Researchers led by Lin et al. reported an engineered ACE2 decoy receptor that neutralizes multiple SARS-CoV-2 variants in vitro, including escape mutants. The work, published in the Journal of Biomedical Science, shows the decoy binds viral spike proteins and prevents cell entry across tested mutants. The study provides a platform approach to broad-spectrum viral neutralization: by mimicking the host receptor, the decoy reduces reliance on variant-specific antibodies. Authors argue the decoy could complement vaccines and monoclonal therapies, particularly where antigenic drift undermines antibody efficacy.